Early drug development: strategies and routes to first-in-human trials
Saved in:
| Format: | Electronic eBook |
|---|---|
| Language: | English |
| Published: |
Hoboken, N.J.
Wiley
c2010
|
| Subjects: | |
| Online Access: | TUM01 Volltext |
| Item Description: | Includes bibliographical references and index Drug discovery and early drug development / Mitchell N. Cayen -- ADME strategies in lead optimization / Amin A. Nomeir -- Prediction of pharmacokinetics and drug safety in humans / Peter L. Bullock -- Bioanalytical strategies / Christopher Kemper -- Chemistry, manufacturing and controls : the drug substance and formulated drug product / Orn Almarsson and Christopher J. Galli -- Nonclinical safety pharmacology studies recommended for support of first-in-human clinical trials / Duane B. Lakings -- Toxicology program to support initiation of a clinical phase I program for a new medicine / Hugh E. Black, Stephen B. Montgomery, and Ronald W. Moch -- Toxicokinetics in support of drug development / Gary Eichenbaum, Vangala Subrahmanyam, and Alfred P. Tonelli -- Good laboratory practice / Anthony B. Jones, Kathryn Hackett-Fields, and Shari L. Perlstein -- Estimation of human starting dose for phase I clinical programs / Lorrene A. Buckley ... [et al.] -- Exploratory INDS/CTAS / Mitchell N. Cayen -- Unique considerations for biopharmaceutics / Laura P. Andrews and James D. Green -- Project management and international regulatory requirements for first-in-human trials / Carolyn D. Finkle and Judith Atkins -- First-in-human regulatory submissions / Mary M. Sommer ... [et al.] |
| Physical Description: | 1 Online-Ressource (xxv, 630 p.) |
| ISBN: | 0470613173 047061319X 9780470613177 9780470613191 |
Staff View
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV040473063 | ||
| 003 | DE-604 | ||
| 005 | 20130723 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 121011s2010 |||| o||u| ||||||eng d | ||
| 020 | |a 0470613173 |c electronic bk. |9 0-470-61317-3 | ||
| 020 | |a 047061319X |c electronic bk. |9 0-470-61319-X | ||
| 020 | |a 9780470613177 |c electronic bk. |9 978-0-470-61317-7 | ||
| 020 | |a 9780470613191 |c electronic bk. |9 978-0-470-61319-1 | ||
| 035 | |a (OCoLC)874193013 | ||
| 035 | |a (DE-599)BVBBV040473063 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-91 | ||
| 084 | |a VS 5350 |0 (DE-625)147687:253 |2 rvk | ||
| 245 | 1 | 0 | |a Early drug development |b strategies and routes to first-in-human trials |c edited by Mitchell N. Cayen |
| 264 | 1 | |a Hoboken, N.J. |b Wiley |c c2010 | |
| 300 | |a 1 Online-Ressource (xxv, 630 p.) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Includes bibliographical references and index | ||
| 500 | |a Drug discovery and early drug development / Mitchell N. Cayen -- ADME strategies in lead optimization / Amin A. Nomeir -- Prediction of pharmacokinetics and drug safety in humans / Peter L. Bullock -- Bioanalytical strategies / Christopher Kemper -- Chemistry, manufacturing and controls : the drug substance and formulated drug product / Orn Almarsson and Christopher J. Galli -- Nonclinical safety pharmacology studies recommended for support of first-in-human clinical trials / Duane B. Lakings -- Toxicology program to support initiation of a clinical phase I program for a new medicine / Hugh E. Black, Stephen B. Montgomery, and Ronald W. Moch -- Toxicokinetics in support of drug development / Gary Eichenbaum, Vangala Subrahmanyam, and Alfred P. Tonelli -- Good laboratory practice / Anthony B. Jones, Kathryn Hackett-Fields, and Shari L. Perlstein -- Estimation of human starting dose for phase I clinical programs / Lorrene A. Buckley ... [et al.] -- Exploratory INDS/CTAS / Mitchell N. Cayen -- Unique considerations for biopharmaceutics / Laura P. Andrews and James D. Green -- Project management and international regulatory requirements for first-in-human trials / Carolyn D. Finkle and Judith Atkins -- First-in-human regulatory submissions / Mary M. Sommer ... [et al.] | ||
| 650 | 7 | |a MEDICAL / Drug Guides |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Pharmacy |2 bisacsh | |
| 650 | 7 | |a MEDICAL / Nursing / Pharmacology |2 bisacsh | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Drug development | |
| 650 | 4 | |a Drug Discovery / methods | |
| 650 | 4 | |a Clinical Trials, Phase I as Topic | |
| 650 | 4 | |a Drug Approval / organization & administration | |
| 650 | 4 | |a Drugs, Investigational / therapeutic use | |
| 650 | 4 | |a Research Design | |
| 650 | 4 | |a MEDICAL / Drug Guides / bisacsh | |
| 650 | 4 | |a MEDICAL / Pharmacology / bisacsh | |
| 650 | 4 | |a MEDICAL / Pharmacy / bisacsh | |
| 650 | 4 | |a MEDICAL / Nursing / Pharmacology / bisacsh | |
| 650 | 0 | 7 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Klinische Prüfung |0 (DE-588)4031192-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Arzneimittelentwicklung |0 (DE-588)4143176-5 |D s |
| 689 | 0 | 1 | |a Klinische Prüfung |0 (DE-588)4031192-2 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 700 | 1 | |a Cayen, Mitchell N. |e Sonstige |4 oth | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-0-470-17086-1 |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=335253 |x Verlag |3 Volltext |
| 912 | |a ZDB-4-NLEBK | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-025320352 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=335253 |l TUM01 |p ZDB-4-NLEBK |q TUM_PDA_EBSCO_MED_gekauft |x Verlag |3 Volltext | |
Record in the Search Index
| _version_ | 1804149536686342144 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV040473063 |
| classification_rvk | VS 5350 |
| collection | ZDB-4-NLEBK |
| ctrlnum | (OCoLC)874193013 (DE-599)BVBBV040473063 |
| discipline | Chemie / Pharmazie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04019nmm a2200649zc 4500</leader><controlfield tag="001">BV040473063</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20130723 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">121011s2010 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0470613173</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-470-61317-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">047061319X</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">0-470-61319-X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780470613177</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-470-61317-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780470613191</subfield><subfield code="c">electronic bk.</subfield><subfield code="9">978-0-470-61319-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)874193013</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV040473063</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 5350</subfield><subfield code="0">(DE-625)147687:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Early drug development</subfield><subfield code="b">strategies and routes to first-in-human trials</subfield><subfield code="c">edited by Mitchell N. Cayen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, N.J.</subfield><subfield code="b">Wiley</subfield><subfield code="c">c2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xxv, 630 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Drug discovery and early drug development / Mitchell N. Cayen -- ADME strategies in lead optimization / Amin A. Nomeir -- Prediction of pharmacokinetics and drug safety in humans / Peter L. Bullock -- Bioanalytical strategies / Christopher Kemper -- Chemistry, manufacturing and controls : the drug substance and formulated drug product / Orn Almarsson and Christopher J. Galli -- Nonclinical safety pharmacology studies recommended for support of first-in-human clinical trials / Duane B. Lakings -- Toxicology program to support initiation of a clinical phase I program for a new medicine / Hugh E. Black, Stephen B. Montgomery, and Ronald W. Moch -- Toxicokinetics in support of drug development / Gary Eichenbaum, Vangala Subrahmanyam, and Alfred P. Tonelli -- Good laboratory practice / Anthony B. Jones, Kathryn Hackett-Fields, and Shari L. Perlstein -- Estimation of human starting dose for phase I clinical programs / Lorrene A. Buckley ... [et al.] -- Exploratory INDS/CTAS / Mitchell N. Cayen -- Unique considerations for biopharmaceutics / Laura P. Andrews and James D. Green -- Project management and international regulatory requirements for first-in-human trials / Carolyn D. Finkle and Judith Atkins -- First-in-human regulatory submissions / Mary M. Sommer ... [et al.]</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Drug Guides</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacy</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Nursing / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Discovery / methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical Trials, Phase I as Topic</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Approval / organization & administration</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs, Investigational / therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Research Design</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MEDICAL / Drug Guides / bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MEDICAL / Pharmacology / bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MEDICAL / Pharmacy / bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">MEDICAL / Nursing / Pharmacology / bisacsh</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Klinische Prüfung</subfield><subfield code="0">(DE-588)4031192-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Arzneimittelentwicklung</subfield><subfield code="0">(DE-588)4143176-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Klinische Prüfung</subfield><subfield code="0">(DE-588)4031192-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cayen, Mitchell N.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-0-470-17086-1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=335253</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-025320352</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=335253</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-4-NLEBK</subfield><subfield code="q">TUM_PDA_EBSCO_MED_gekauft</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV040473063 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T00:24:36Z |
| institution | BVB |
| isbn | 0470613173 047061319X 9780470613177 9780470613191 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-025320352 |
| oclc_num | 874193013 |
| open_access_boolean | |
| owner | DE-91 DE-BY-TUM |
| owner_facet | DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (xxv, 630 p.) |
| psigel | ZDB-4-NLEBK ZDB-4-NLEBK TUM_PDA_EBSCO_MED_gekauft |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Wiley |
| record_format | marc |
| spelling | Early drug development strategies and routes to first-in-human trials edited by Mitchell N. Cayen Hoboken, N.J. Wiley c2010 1 Online-Ressource (xxv, 630 p.) txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index Drug discovery and early drug development / Mitchell N. Cayen -- ADME strategies in lead optimization / Amin A. Nomeir -- Prediction of pharmacokinetics and drug safety in humans / Peter L. Bullock -- Bioanalytical strategies / Christopher Kemper -- Chemistry, manufacturing and controls : the drug substance and formulated drug product / Orn Almarsson and Christopher J. Galli -- Nonclinical safety pharmacology studies recommended for support of first-in-human clinical trials / Duane B. Lakings -- Toxicology program to support initiation of a clinical phase I program for a new medicine / Hugh E. Black, Stephen B. Montgomery, and Ronald W. Moch -- Toxicokinetics in support of drug development / Gary Eichenbaum, Vangala Subrahmanyam, and Alfred P. Tonelli -- Good laboratory practice / Anthony B. Jones, Kathryn Hackett-Fields, and Shari L. Perlstein -- Estimation of human starting dose for phase I clinical programs / Lorrene A. Buckley ... [et al.] -- Exploratory INDS/CTAS / Mitchell N. Cayen -- Unique considerations for biopharmaceutics / Laura P. Andrews and James D. Green -- Project management and international regulatory requirements for first-in-human trials / Carolyn D. Finkle and Judith Atkins -- First-in-human regulatory submissions / Mary M. Sommer ... [et al.] MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Medizin Drug development Drug Discovery / methods Clinical Trials, Phase I as Topic Drug Approval / organization & administration Drugs, Investigational / therapeutic use Research Design MEDICAL / Drug Guides / bisacsh MEDICAL / Pharmacology / bisacsh MEDICAL / Pharmacy / bisacsh MEDICAL / Nursing / Pharmacology / bisacsh Arzneimittelentwicklung (DE-588)4143176-5 gnd rswk-swf Klinische Prüfung (DE-588)4031192-2 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Arzneimittelentwicklung (DE-588)4143176-5 s Klinische Prüfung (DE-588)4031192-2 s 2\p DE-604 Cayen, Mitchell N. Sonstige oth Erscheint auch als Druck-Ausgabe, Hardcover 978-0-470-17086-1 http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=335253 Verlag Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Early drug development strategies and routes to first-in-human trials MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Medizin Drug development Drug Discovery / methods Clinical Trials, Phase I as Topic Drug Approval / organization & administration Drugs, Investigational / therapeutic use Research Design MEDICAL / Drug Guides / bisacsh MEDICAL / Pharmacology / bisacsh MEDICAL / Pharmacy / bisacsh MEDICAL / Nursing / Pharmacology / bisacsh Arzneimittelentwicklung (DE-588)4143176-5 gnd Klinische Prüfung (DE-588)4031192-2 gnd |
| subject_GND | (DE-588)4143176-5 (DE-588)4031192-2 (DE-588)4143413-4 |
| title | Early drug development strategies and routes to first-in-human trials |
| title_auth | Early drug development strategies and routes to first-in-human trials |
| title_exact_search | Early drug development strategies and routes to first-in-human trials |
| title_full | Early drug development strategies and routes to first-in-human trials edited by Mitchell N. Cayen |
| title_fullStr | Early drug development strategies and routes to first-in-human trials edited by Mitchell N. Cayen |
| title_full_unstemmed | Early drug development strategies and routes to first-in-human trials edited by Mitchell N. Cayen |
| title_short | Early drug development |
| title_sort | early drug development strategies and routes to first in human trials |
| title_sub | strategies and routes to first-in-human trials |
| topic | MEDICAL / Drug Guides bisacsh MEDICAL / Pharmacology bisacsh MEDICAL / Pharmacy bisacsh MEDICAL / Nursing / Pharmacology bisacsh Medizin Drug development Drug Discovery / methods Clinical Trials, Phase I as Topic Drug Approval / organization & administration Drugs, Investigational / therapeutic use Research Design MEDICAL / Drug Guides / bisacsh MEDICAL / Pharmacology / bisacsh MEDICAL / Pharmacy / bisacsh MEDICAL / Nursing / Pharmacology / bisacsh Arzneimittelentwicklung (DE-588)4143176-5 gnd Klinische Prüfung (DE-588)4031192-2 gnd |
| topic_facet | MEDICAL / Drug Guides MEDICAL / Pharmacology MEDICAL / Pharmacy MEDICAL / Nursing / Pharmacology Medizin Drug development Drug Discovery / methods Clinical Trials, Phase I as Topic Drug Approval / organization & administration Drugs, Investigational / therapeutic use Research Design MEDICAL / Drug Guides / bisacsh MEDICAL / Pharmacology / bisacsh MEDICAL / Pharmacy / bisacsh MEDICAL / Nursing / Pharmacology / bisacsh Arzneimittelentwicklung Klinische Prüfung Aufsatzsammlung |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=335253 |
| work_keys_str_mv | AT cayenmitchelln earlydrugdevelopmentstrategiesandroutestofirstinhumantrials |